Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PBH SEC filings page on Stock Titan provides access to regulatory documents for Prestige Consumer Healthcare Inc., a New York Stock Exchange–listed consumer healthcare products company. These filings offer detailed information on the company’s financial condition, operations and material events related to its over-the-counter (OTC) healthcare brands.
Prestige’s periodic reports, such as its annual and quarterly filings, describe performance in its North American OTC Healthcare and International OTC Healthcare segments, along with discussions of revenues, operating income, net income, earnings per share, free cash flow and leverage. They also provide context on category trends across gastrointestinal, women’s health, cough and cold, eye and ear care and other consumer health areas, as well as the role of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
Current reports on Form 8-K, several of which are referenced in the provided data, disclose events such as the release of quarterly earnings, the use of investor presentations and the entry into a material definitive agreement to acquire Pillar5 Pharma Inc., a Canadian sterile ophthalmic manufacturer and current Clear Eyes® supplier. These filings outline key terms of the transaction, closing conditions and related risk considerations.
On Stock Titan, users can view Prestige Consumer Healthcare’s filings as they are made available through EDGAR and use AI-powered summaries to interpret complex sections. This includes understanding how management presents non-GAAP measures like adjusted net income and adjusted diluted earnings per share, as well as reviewing risk factor discussions, segment information and material agreements that shape the company’s OTC healthcare business.
The Vanguard Group filed Amendment No. 17 to its Schedule 13G/A regarding Prestige Consumer Healthcare Inc. The amendment reports amount beneficially owned: 0 shares representing 0% of Common Stock. It explains an internal realignment effective January 12, 2026 that caused disaggregated reporting by Vanguard subsidiaries. The form is signed by Ashley Grim on 03/27/2026.
Prestige Consumer Healthcare Inc. announced a definitive agreement for its subsidiary Prestige Brands, Inc. to acquire the Breathe Right nasal strip brand and certain other over-the-counter consumer health brands from Foundation Consumer Healthcare for $1.045 billion in cash, or approximately $900 million net of anticipated $150 million tax benefits. The assets include Breathe Right, the leading nasal strip brand in the United States with international sales, and brands such as Dimetapp children’s cough and cold relief. The deal is expected to close in the first half of fiscal 2027, subject to customary closing conditions and antitrust clearance, and will be financed with cash on hand and a new Term Loan facility. Management describes the acquisition as margin-accretive and expects it to increase free cash flow and support faster balance-sheet deleveraging.
Prestige Consumer Healthcare Inc. Senior VP of Operations Jeffrey Zerillo reported an open-market sale of common stock. On February 11, 2026, he sold 1,000 shares of Prestige Consumer common stock at $65.93 per share. After this transaction, he directly owned 41,048 shares of the company’s common stock.
Ariel Investments, LLC has reported beneficial ownership of 4,102,497 shares of Prestige Consumer Healthcare Inc common stock, representing 8.5% of the outstanding class as of December 31, 2025. Ariel has sole voting power over 3,672,254 shares and sole dispositive power over all 4,102,497 shares.
The filing explains that these securities are held for Ariel’s adviser clients, who are entitled to dividends and sale proceeds, and that no individual client has an economic interest in more than 5% of the shares. Ariel certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Prestige Consumer Healthcare.
A person associated with PBH has filed a notice of intent to sell 1,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 65,930.00. The filing shows 47,318,730 shares of this class outstanding. The shares to be sold were acquired through restricted stock vesting on May 2, 2024, May 5, 2025, and May 7, 2025, in amounts of 116, 533, and 351 shares respectively, all as compensation. Over the past three months, the filer previously sold 719 shares on November 28, 2025 for gross proceeds of 43,140.00 and 281 shares on December 1, 2025 for gross proceeds of 16,860.00.
Prestige Consumer Healthcare Inc. reported softer results for the quarter ended December 31, 2025. Total revenues slipped 2.4% to $283.4 million, with declines in both North American and International OTC segments, mainly from weaker Eye & Ear Care sales. Quarterly net income fell to $46.7 million, or $0.97 per diluted share, down from $61.0 million and $1.22 a year earlier, reflecting lower sales, higher general and administrative costs and a $10.3 million supplier loan write-off.
For the first nine months of fiscal 2026, revenues declined 4.1% to $807.1 million and net income decreased to $136.4 million from $164.5 million, while gross margin ticked higher on favorable mix. The company completed two acquisitions, including Pillar5 Pharma for a preliminary $111.9 million, added goodwill and intangibles, generated strong operating cash flow of $214.8 million, and used $155.6 million to repurchase shares, ending with $62.4 million in cash and $1.04 billion of long-term debt.
Prestige Consumer Healthcare Inc. filed a current report to share that it has announced financial results for the fiscal quarter and nine months ended December 31, 2025. The detailed numbers are provided in a separate earnings press release attached as Exhibit 99.1.
The company is also using an investor presentation, attached as Exhibit 99.2, to discuss these results with investors, analysts and others during the fiscal year ending March 31, 2026. Both the press release and presentation are being treated as “furnished,” meaning they are provided for information and are not classified as formally filed financial statements under securities laws.
Prestige Consumer Healthcare senior vice president Jose Luis Rosado reported receiving 3,426 shares of common stock on January 6, 2026, at a price of $0 per share, bringing his direct holdings to 3,436 shares.
The award represents restricted stock units that are scheduled to fully vest on January 6, 2030, indicating a long-term, equity-based component to his compensation aligned with the company’s future performance.
Prestige Consumer Healthcare executive Jose Luis Rosado filed an initial insider ownership report. As of January 6, 2026, he beneficially owns 10 shares of common stock, held directly. Rosado serves as SVP – Quality & Regulatory Affairs. No derivative securities are reported.
Prestige Consumer Healthcare Inc. officer Jeffrey Zerillo, Senior VP Operations, reported two open-market sales of company stock. On 11/28/2025, he sold 719 shares of common stock at $60 per share, leaving him with 42,329 shares beneficially owned afterward. On 12/01/2025, he sold an additional 281 shares at $60 per share, reducing his holdings to 42,048 shares.
The filing is a Form 4, which discloses changes in ownership by company insiders and confirms that Zerillo’s holdings remain directly owned after these transactions.